Method, device, medium and equipment for judging insufficient dose of hemolytic agent
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SHENZHEN COMEN MEDICAL INSTR
- Filing Date
- 2023-09-21
- Publication Date
- 2026-07-03
Smart Images
Figure CN117191675B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of hemolytic agents, and in particular to a method, apparatus, medium, and device for determining insufficient hemolytic agent dosage. Background Technology
[0002] Blood cell analyzers can count various blood cells in the blood. For example, in one scenario, when 5LDS hemolysin is mixed with a fresh blood sample, red blood cells are dissolved and white blood cells are stained. Then, 5LHS hemolysin is added. 5LHS basic hemolysin exposes the nuclei of white blood cells except for basophils (BASO), making BASO cells significantly different in size from the other cells, thus distinguishing BASO cells.
[0003] Detection principle as follows Figure 1 As shown, the cells to be tested are arranged in a single row under the sheath fluid and flow into the flow chamber at a constant speed. Under the illumination of the laser beam, three different angles of scattered light are generated. The magnitude of the scattered light generated by the cells irradiated by the laser beam is related to the cell size, the refractive index of the cell membrane and the complexity of the internal organs of the cell. The scattered light signal is finally converted into an electrical pulse signal. Based on the collected electrical pulse data, the scatter plot distribution of white blood cells under three-dimensional signal can be obtained. Finally, the classification result of white blood cells is obtained based on the white blood cell scatter plot.
[0004] When a blood cell analyzer measures a sample, for example, if the required 5LHS hemolysing reagent is insufficient in the scenario described above, the white blood cell scatter plot will appear abnormal, leading to abnormal white blood cell classification and ultimately inaccurate cell count results. Traditional methods for detecting the remaining hemolysing reagent level involve using sensors to detect the hemolysing reagent level. However, this method requires hardware support, its principle is complex, the device is large, and due to the numerous components, a malfunction in any one component can prevent the entire detection device from functioning properly. Furthermore, sensor detection is significantly affected by interference factors, such as the most common bubble interference; the presence of bubbles may lead to a false positive for insufficient hemolysing reagent. Therefore, a simple, fast, and effective method is needed to provide an alert when the hemolysing reagent level is insufficient. Summary of the Invention
[0005] Therefore, it is necessary to provide methods, devices, media, and equipment for judging insufficient hemolytic agent dosage, in order to solve the problem that traditional sensor monitoring methods require hardware support and are difficult to monitor accurately.
[0006] A method for determining insufficient dosage of hemolytic agent, the method comprising:
[0007] Acquire a set of pulse signals of a target blood cell sample at a preset scattering angle; wherein, the target blood cell sample is any one of a plurality of experimental blood cell samples, and the plurality of experimental blood cell samples are all blood cell samples obtained after treatment with sufficient hemolysing agent;
[0008] The signal intensity of each pulse signal in the pulse signal set is identified, and the particle distribution of the signal intensity is statistically analyzed; wherein, the particle distribution is used to indicate the number of blood cell particles with different signal intensities;
[0009] The dispersion of the target blood cell sample in signal intensity is calculated based on the particle distribution to obtain the dispersion of multiple experimental blood cell samples.
[0010] The allowable range of dispersion is determined by combining the dispersion of the multiple experimental blood cell samples;
[0011] The degree of dispersion of the blood cell sample to be tested in terms of signal intensity is calculated. If the degree of dispersion is not within the allowable range, the current dose of hemolytic agent is determined to be insufficient. The blood cell sample to be tested is the blood cell sample obtained after treatment with the current hemolytic agent.
[0012] In one embodiment, calculating the dispersion of the target blood cell sample in signal intensity based on the particle distribution includes:
[0013] Calculate the mean and standard deviation of the number of different signal intensities based on the particle distribution.
[0014] The coefficient of variation is calculated based on the mean and standard deviation of the frequency, and the coefficient of variation is used as the degree of dispersion of the target blood cell sample in terms of signal intensity.
[0015] In one embodiment, the formula for calculating the average number of occurrences is:
[0016]
[0017] In the above formula, Instruction No. The number of particles of signal strength class, where N is the total number of signal strength classes. Indicates the average of the stated times;
[0018] The formula for calculating the standard deviation of the frequency is:
[0019]
[0020] In the above formula, Indicates the standard deviation of the number;
[0021] The formula for calculating the coefficient of variation is:
[0022]
[0023] In the above formula, Indicates the coefficient of variation.
[0024] In one embodiment, determining the allowable range of dispersion based on the dispersion of the plurality of experimental blood cell samples includes:
[0025] Calculate the mean of the dispersion of the multiple experimental blood cell samples to obtain the mean dispersion.
[0026] Calculate the mean of the frequency standard deviations for the multiple experimental blood cell samples to obtain the mean frequency standard deviation;
[0027] The allowable range of dispersion is determined based on the mean of the degree of dispersion and the mean of the standard deviation of the frequency.
[0028] In one embodiment, the formula for calculating the mean of dispersion is:
[0029]
[0030] In the above formula, The mean of the dispersion; Indicates the dispersion of the k-th experimental blood cell sample. Indicator test blood cell count;
[0031] The formula for calculating the mean of the standard deviation of the frequency is:
[0032]
[0033] In the above formula, Mean of standard deviation of the number of indications; Indicates the standard deviation of the number of blood cell samples in the k-th experiment;
[0034] The discrete allowable range is expressed as:
[0035]
[0036] In the above formula, The default value is less than 1.
[0037] In one embodiment, after the particle distribution of the statistical signal intensity, the method further includes:
[0038] The particle distribution is filtered; the filtering formula is as follows:
[0039]
[0040] In the above formula, This shows the particle distribution after filtering. This represents the particle distribution before filtering, where i indicates the intensity of the i-th type of signal, and N indicates the total number of signal types. Indicator mean, Indicative standard deviation.
[0041] A device for determining insufficient dosage of hemolytic agent, the device comprising:
[0042] A discrete allowable range determination module is used to acquire a set of pulse signals from a target blood cell sample at a preset scattering angle; wherein the target blood cell sample is any one of multiple experimental blood cell samples, all of which are blood cell samples obtained after sufficient hemolytic agent treatment; the module identifies the signal intensity of each pulse signal in the pulse signal set and statistically analyzes the particle distribution of the signal intensity; wherein the particle distribution indicates the number of blood cell particles at different signal intensities; the module calculates the discreteness of the target blood cell sample in terms of signal intensity based on the particle distribution to obtain the discreteness of the multiple experimental blood cell samples; and the discrete allowable range is determined by combining the discreteness of the multiple experimental blood cell samples.
[0043] The judgment module is used to calculate the degree of dispersion of the blood cell sample to be tested in terms of signal intensity. If the degree of dispersion is not within the allowable range of dispersion, it is determined that the current dose of hemolytic agent is insufficient. The blood cell sample to be tested is a blood cell sample obtained after treatment with the current hemolytic agent.
[0044] A computer-readable storage medium storing a computer program, which, when executed by a processor, causes the processor to perform the steps of the above-described method for determining insufficient hemolytic agent dosage.
[0045] A device for determining insufficient hemolytic agent dosage includes a memory and a processor. The memory stores a computer program, which, when executed by the processor, causes the processor to perform the steps of the aforementioned method for determining insufficient hemolytic agent dosage.
[0046] This invention provides a method, apparatus, medium, and device for determining insufficient hemolytic agent dosage. It eliminates the need for a dose sensor, requiring only the prior experimental determination of the allowable dispersion range. This includes acquiring a set of pulse signals from a target blood cell sample at a preset scattering angle; identifying the signal intensity of each pulse signal in the set and statistically analyzing the particle distribution of the signal intensity; calculating the dispersion of the target blood cell sample in signal intensity based on the particle distribution to obtain the dispersion of multiple experimental blood cell samples; and combining the dispersion of multiple experimental blood cell samples to determine the allowable dispersion range. Next, the measured dispersion of the target blood cell sample after treatment with the current hemolytic agent is calculated. If the measured dispersion is not within the allowable dispersion range, the dosage of the currently used hemolytic agent is determined to be insufficient. This invention determines the remaining amount of the currently used hemolytic agent by real-time monitoring the dispersion of the target blood cell sample after treatment with the current hemolytic agent. This reduces the cost of instrument detection, simplifies the instrument structure, and ensures sufficient accuracy because it is not affected by interference factors such as air bubbles. Attached Figure Description
[0047] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.
[0048] in:
[0049] Figure 1 This is a schematic diagram illustrating the principle of white blood cell monitoring.
[0050] Figure 2 A flowchart illustrating the method for determining insufficient hemolytic agent dosage;
[0051] Figure 3 A schematic diagram illustrating the generation of scattered light at three different angles;
[0052] Figure 4 This is a schematic diagram showing the degree of dispersion of signal intensity in three blood cell samples (a), (b), and (c).
[0053] Figure 5 This is a schematic diagram of a device for determining insufficient hemolytic agent dosage.
[0054] Figure 6 This is a block diagram of a device for determining insufficient hemolytic agent dosage. Detailed Implementation
[0055] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.
[0056] The terms "first," "second," etc., in the specification, claims, and accompanying drawings of this application are used to distinguish different objects, not to describe a specific order. Furthermore, the terms "comprising" and "having," and any variations thereof, are intended to cover non-exclusive inclusion. For example, a process, method, system, product, or apparatus that includes a series of steps or units is not limited to the listed steps or units, but may optionally include steps or units not listed, or may optionally include other steps or units inherent to these processes, methods, products, or apparatuses.
[0057] In this document, the term "embodiment" means that a particular feature, structure, or characteristic described in connection with an embodiment may be included in at least one embodiment of this application. The appearance of this phrase in various places throughout the specification does not necessarily refer to the same embodiment, nor is it a separate or alternative embodiment mutually exclusive with other embodiments. It will be explicitly and implicitly understood by those skilled in the art that the embodiments described herein can be combined with other embodiments.
[0058] like Figure 2 As shown, Figure 2 This is a flowchart illustrating a method for determining insufficient hemolytic agent dosage in one embodiment. The steps provided by the method for determining insufficient hemolytic agent dosage in this embodiment include:
[0059] S201, acquire the pulse signal set of the target blood cell sample at a preset scattering angle.
[0060] The target blood cell sample is any one of multiple experimental blood cell samples, and all of the multiple experimental blood cell samples are blood cell samples obtained after being treated with sufficient hemolysing agent.
[0061] For example, in one scenario, the number of experimental blood cell samples is K. These K samples are first treated with sufficient 5LDS hemolysing agent, then with sufficient 5LHS hemolysing agent, resulting in white blood cells and red blood cell fragments. Enveloped in sheath fluid, the cells arrange themselves in a single row and flow uniformly into the flow chamber. Under laser beam irradiation, as per [reference / reference / reference]... Figure 3This generates scattered light at three different angles: low-angle, medium-angle, and high-angle scattered light. Low-angle scattered light refers to light scattered from the forward low-angle region, medium-angle scattered light from the forward medium-angle region, and high-angle scattered light from the side high-angle region. Low-angle scattered light reflects cell size, medium-angle scattered light reflects the fine internal structure and granular material of the cell, and high-angle forward scattered light also reflects the fine internal structure and granular material of the cell. An aperture in the receiving section is used to determine the presence of scattered light. The first receiver receives the medium-angle scattered light emitted from the flow chamber and converts it into a medium-angle pulse signal, forming the pulse signal set corresponding to the medium angle. The second receiver receives the high-angle scattered light emitted from the flow chamber and converts it into a high-angle pulse signal, forming the pulse signal set corresponding to the high angle. The third receiver receives the low-angle scattered light emitted from the flow chamber and converts it into a low-angle pulse signal, forming the pulse signal set corresponding to the low angle. In this embodiment, any one of the pulse signal sets at a preset scattering angle can be selected to construct a discrete allowable range.
[0062] S202, identify the signal strength of each pulse signal in the pulse signal set, and statistically analyze the particle distribution of the signal strength.
[0063] In this step, the signal strength of each pulse signal can be identified using existing pulse recognition algorithms, such as threshold detection algorithms or energy threshold algorithms. Then, the signal strengths of all pulse signals are summarized to obtain... , indicating the first in the sample The signal intensity of the pulse signal of each white blood cell, among which This indicates the total number of pulse signals.
[0064] Next, the particle distribution based on signal intensity is analyzed. This particle distribution indicates the number of blood cell particles at different signal intensities. Instruction No. The number of particles of each signal strength class, where N is the total number of signal strength classes.
[0065] In one specific embodiment, the particle distribution is further filtered; wherein the filtering formula is:
[0066]
[0067] In the above formula, This shows the particle distribution after filtering. This represents the particle distribution before filtering, where i indicates the intensity of the i-th type of signal, and N indicates the total number of signal types. Indicator mean, Indicative standard deviation.
[0068] After the above filtering process, noise in the particle distribution can be effectively removed, making the overall distribution smoother.
[0069] S203, calculate the dispersion of the target blood cell sample in signal intensity based on the particle distribution, so as to obtain the dispersion of multiple experimental blood cell samples.
[0070] This degree of dispersion is used to determine the stability of a signal. In other words, the greater the degree of dispersion, the more unstable the signal; conversely, the smaller the degree of dispersion, the more stable the signal.
[0071] In one specific embodiment, the dispersion of the target blood cell sample in signal intensity is calculated as follows:
[0072] (1) Calculate the mean and standard deviation of the number of different signal intensities based on the particle distribution.
[0073] The formula for calculating the mean of the frequencies is as follows:
[0074]
[0075] In the above formula, Instruction No. The number of particles of signal strength class, where N is the total number of signal strength classes. The average number of times indicated.
[0076] The formula for calculating the standard deviation of the frequency is:
[0077]
[0078] In the above formula, Standard deviation of the indicated number of times.
[0079] (2) Calculate the coefficient of variation based on the mean and standard deviation of the number of times, and use the coefficient of variation as the degree of dispersion of the target blood cell sample in terms of signal intensity.
[0080] The formula for calculating the coefficient of variation is as follows:
[0081]
[0082] In the above formula, Indicator coefficient of variation.
[0083] Of course, the above specific embodiments can calculate the dispersion of a target blood cell sample in terms of signal intensity. By repeatedly performing the above steps on all experimental blood cell samples, the dispersion of all experimental blood cell samples can be obtained.
[0084] S204, determine the allowable range of dispersion by combining the dispersion of multiple experimental blood cell samples.
[0085] In a specific implementation, the discrete allowable range is determined as follows:
[0086] (1) Calculate the mean of the dispersion of multiple experimental blood cell samples to obtain the mean of dispersion.
[0087] The formula for calculating the mean of dispersion is as follows:
[0088]
[0089] In the above formula, The mean of the dispersion; Indicates the dispersion of the k-th experimental blood cell sample. Total number of blood cells in an indicator experiment.
[0090] (2) Calculate the mean of the frequency standard deviations of multiple experimental blood cell samples to obtain the mean frequency standard deviation.
[0091] The formula for calculating the mean of the standard deviation of frequencies is:
[0092]
[0093] In the above formula, Mean of standard deviation of the number of indications; Indicates the standard deviation of the number of times the k-th experimental blood cell sample is taken.
[0094] (3) Determine the allowable range of dispersion based on the mean of the degree of dispersion and the mean of the standard deviation of the frequency.
[0095] Optionally, the discrete allowable range is expressed as:
[0096]
[0097] In the above formula, The default value is less than 1. The smaller the value, the smaller the allowable range of dispersion, and the more stringent the determination of reagent balance. Of course, this specific value can be set according to the actual situation.
[0098] S205, calculate the degree of dispersion of the blood cell sample to be tested in terms of signal intensity. If the degree of dispersion is not within the allowable range, the current dose of hemolytic agent is determined to be insufficient.
[0099] The blood cell sample to be tested is the blood cell sample obtained after treatment with the current hemolysing agent. The method for calculating the dispersion is the same as steps S201-S203 above, except that it is unknown whether the dosage of the current hemolysing agent is sufficient. If the dispersion of the sample to be tested is not within the allowable dispersion range, it is determined that the dosage of the current hemolysing agent is insufficient.
[0100] For example, in a practical experiment, the measured discrete allowable range is [22, 28], while the discreteness of the signal intensity of the three blood cell samples (a), (b), and (c) is as follows: Figure 4 As shown in the figure, the dispersion of (a) is 24.98, which is within the allowable dispersion range, indicating that the dosage of the hemolytic agent used in (a) is sufficient. However, the dispersion of (b) is 32.18 and that of (c) is 39.29, both outside the allowable dispersion range, indicating that the dosage of the hemolytic agent used in (b) and (c) is insufficient. This also shows that the insufficient dosage of the hemolytic agent used in (c) is more severe.
[0101] This invention provides a method, apparatus, medium, and device for determining insufficient hemolytic agent dosage. It eliminates the need for a dose sensor, requiring only the prior experimental determination of the allowable dispersion range. This includes acquiring a set of pulse signals from a target blood cell sample at a preset scattering angle; identifying the signal intensity of each pulse signal in the set and statistically analyzing the particle distribution of the signal intensity; calculating the dispersion of the target blood cell sample in signal intensity based on the particle distribution to obtain the dispersion of multiple experimental blood cell samples; and combining the dispersion of multiple experimental blood cell samples to determine the allowable dispersion range. Next, the measured dispersion of the target blood cell sample after treatment with the current hemolytic agent is calculated. If the measured dispersion is not within the allowable dispersion range, the dosage of the currently used hemolytic agent is determined to be insufficient. This invention determines the remaining amount of the currently used hemolytic agent by real-time monitoring the dispersion of the target blood cell sample after treatment with the current hemolytic agent. This reduces the cost of instrument detection, simplifies the instrument structure, and ensures sufficient accuracy because it is not affected by interference factors such as air bubbles.
[0102] In one embodiment, such as Figure 5 As shown, a device for determining insufficient hemolytic agent dosage is proposed, the device comprising:
[0103] The discrete allowable range determination module 501 is used to acquire a set of pulse signals of a target blood cell sample at a preset scattering angle; wherein the target blood cell sample is any one of multiple experimental blood cell samples, and the multiple experimental blood cell samples are all blood cell samples obtained after sufficient hemolytic agent treatment; the module identifies the signal intensity of each pulse signal in the pulse signal set and counts the particle distribution of the signal intensity; wherein the particle distribution is used to indicate the number of blood cell particles with different signal intensities; the module calculates the discreteness of the target blood cell sample in terms of signal intensity based on the particle distribution to obtain the discreteness of multiple experimental blood cell samples; and determines the discrete allowable range by combining the discreteness of multiple experimental blood cell samples.
[0104] The judgment module 502 is used to calculate the degree of dispersion of the blood cell sample to be tested in terms of signal intensity. If the degree of dispersion is not within the allowable range, it is determined that the current dose of hemolytic agent is insufficient. The blood cell sample to be tested is the blood cell sample obtained after being treated with the current hemolytic agent.
[0105] In one embodiment, the discrete allowable range determination module is specifically used to: calculate the mean and standard deviation of the number of different signal intensities based on the particle distribution; calculate the coefficient of variation based on the mean and standard deviation of the number of times, and use the coefficient of variation as the degree of dispersion of the target blood cell sample in terms of signal intensity.
[0106] In one embodiment, the formula for calculating the mean of the number of occurrences is:
[0107]
[0108] In the above formula, Instruction No. The number of particles of signal strength class, where N is the total number of signal strength classes. Mean of the number of indications;
[0109] The formula for calculating the standard deviation of frequencies is:
[0110]
[0111] In the above formula, Standard deviation of the indicated frequency;
[0112] The formula for calculating the coefficient of variation is:
[0113]
[0114] In the above formula, Indicator coefficient of variation.
[0115] In one embodiment, the discrete allowable range determination module is specifically used to: calculate the mean of the discreteness of multiple experimental blood cell samples to obtain the mean of the discreteness; calculate the mean of the frequency standard deviation of multiple experimental blood cell samples to obtain the mean of the frequency standard deviation; and determine the discrete allowable range based on the mean of the discreteness and the mean of the frequency standard deviation.
[0116] In one embodiment, the formula for calculating the mean of dispersion is:
[0117]
[0118] In the above formula, The mean of the dispersion; Indicates the dispersion of the k-th experimental blood cell sample. Indicator test blood cell count;
[0119] The formula for calculating the mean of the standard deviation of frequencies is:
[0120]
[0121] In the above formula, Mean of standard deviation of the number of indications; Indicates the standard deviation of the number of blood cell samples in the k-th experiment;
[0122] The discrete allowable range is expressed as:
[0123]
[0124] In the above formula, The default value is less than 1.
[0125] In one embodiment, after statistically analyzing the particle distribution of the signal intensity, the method further includes:
[0126] The particle distribution is filtered; the filtering formula is as follows:
[0127]
[0128] In the above formula, This shows the particle distribution after filtering. This represents the particle distribution before filtering, where i indicates the intensity of the i-th type of signal, and N indicates the total number of signal types. Indicator mean, Indicative standard deviation.
[0129] Figure 6 An internal structural diagram of a device for determining insufficient hemolytic agent dosage is shown in one embodiment. Figure 6 As shown, the device for determining insufficient hemolytic agent dosage includes a processor, a memory, and a network interface connected via a system bus. The memory includes a non-volatile storage medium and internal memory. The non-volatile storage medium stores an operating system and may also store a computer program. When executed by the processor, this computer program enables the processor to implement a method for determining insufficient hemolytic agent dosage. The internal memory may also store a computer program, which, when executed by the processor, enables the processor to implement the method for determining insufficient hemolytic agent dosage. Those skilled in the art will understand that... Figure 6 The structure shown is merely a block diagram of a portion of the structure related to the present application and does not constitute a limitation on the hemolytic agent dosage determination device applied thereto. The specific hemolytic agent dosage determination device may include more or fewer components than those shown in the figure, or combine certain components, or have different component arrangements.
[0130] A computer-readable storage medium storing a computer program, which, when executed by a processor, performs the following steps: acquiring a set of pulse signals of a target blood cell sample at a preset scattering angle; wherein the target blood cell sample is any one of multiple experimental blood cell samples, all of which are blood cell samples obtained after treatment with sufficient hemolysing agent; identifying the signal intensity of each pulse signal in the pulse signal set and statistically analyzing the particle distribution of the signal intensity; wherein the particle distribution is used to indicate the number of blood cell particles at different signal intensities; calculating the dispersion of the target blood cell sample in signal intensity based on the particle distribution to obtain the dispersion of multiple experimental blood cell samples; determining the allowable dispersion range by combining the dispersion of multiple experimental blood cell samples; calculating the undetected dispersion of the blood cell sample to be tested in signal intensity, and if the undetected dispersion is not within the allowable dispersion range, determining that the current dose of hemolysing agent is insufficient; wherein the blood cell sample to be tested is a blood cell sample obtained after treatment with the current hemolysing agent.
[0131] A device for determining insufficient hemolytic agent dosage includes a memory, a processor, and a computer program stored in the memory and executable on the processor. When the processor executes the computer program, it performs the following steps: acquiring a set of pulse signals from a target blood cell sample at a preset scattering angle; wherein the target blood cell sample is any one of multiple experimental blood cell samples, all of which are blood cell samples obtained after treatment with sufficient hemolytic agent; identifying the signal intensity of each pulse signal in the pulse signal set and statistically analyzing the particle distribution of the signal intensity; wherein the particle distribution indicates the number of blood cell particles at different signal intensities; calculating the dispersion of the target blood cell sample in signal intensity based on the particle distribution to obtain the dispersion of multiple experimental blood cell samples; determining the allowable dispersion range by combining the dispersion of multiple experimental blood cell samples; calculating the undetected dispersion of the blood cell sample to be tested in signal intensity; if the undetected dispersion is not within the allowable dispersion range, determining that the current hemolytic agent dosage is insufficient; wherein the blood cell sample to be tested is a blood cell sample obtained after treatment with the current hemolytic agent.
[0132] It should be noted that the above-mentioned method, apparatus, device and computer-readable storage medium for determining insufficient hemolytic agent dosage belong to the same general inventive concept, and the contents of the embodiments of the method, apparatus, device and computer-readable storage medium for determining insufficient hemolytic agent dosage are applicable to each other.
[0133] Those skilled in the art will understand that all or part of the processes in the methods of the above embodiments can be implemented by a computer program instructing related hardware. This program can be stored in a non-volatile computer-readable storage medium, and when executed, it can include the processes of the embodiments of the above methods. Any references to memory, storage, databases, or other media used in the embodiments provided in this application can include non-volatile and / or volatile memory. Non-volatile memory can include read-only memory (ROM), programmable ROM (PROM), electrically programmable ROM (EPROM), electrically erasable programmable ROM (EEPROM), or flash memory. Volatile memory can include random access memory (RAM) or external cache memory. By way of illustration and not limitation, RAM is available in various forms, such as static RAM (SRAM), dynamic RAM (DRAM), synchronous DRAM (SDRAM), dual data rate SDRAM (DDRSDRAM), enhanced SDRAM (ESDRAM), synchronous link DRAM (SLDRAM), RAMbus direct RAM (RDRAM), direct memory bus dynamic RAM (DRDRAM), and RAMbus dynamic RAM (RDRAM), etc.
[0134] The technical features of the above embodiments can be combined in any way. For the sake of brevity, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0135] The above embodiments merely illustrate several implementation methods of this application, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of this patent application. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of this application, and these all fall within the protection scope of this application. Therefore, the protection scope of this patent application should be determined by the appended claims.
Claims
1. A method for determining insufficient dosage of hemolytic agent, characterized in that, The method includes: Acquire a set of pulse signals of a target blood cell sample at a preset scattering angle; wherein, the target blood cell sample is any one of a plurality of experimental blood cell samples, and the plurality of experimental blood cell samples are all blood cell samples obtained after treatment with sufficient hemolysing agent; The signal intensity of each pulse signal in the pulse signal set is identified, and the particle distribution of the signal intensity is statistically analyzed; wherein, the particle distribution is used to indicate the number of blood cell particles with different signal intensities; The dispersion of the target blood cell sample in signal intensity is calculated based on the particle distribution to obtain the dispersion of multiple experimental blood cell samples. The allowable range of dispersion is determined by combining the dispersion of the multiple experimental blood cell samples; The degree of dispersion of the blood cell sample to be tested in terms of signal intensity is calculated. If the degree of dispersion is not within the allowable range, the current dose of hemolytic agent is determined to be insufficient. The blood cell sample to be tested is a blood cell sample obtained after treatment with the current hemolytic agent. The step of calculating the dispersion of the target blood cell sample in signal intensity based on the particle distribution includes: Calculate the mean and standard deviation of the number of different signal intensities based on the particle distribution. The coefficient of variation is calculated based on the mean and standard deviation of the frequency, and the coefficient of variation is used as the degree of dispersion of the target blood cell sample in signal intensity. The step of determining the allowable range of dispersion by considering the dispersion of the multiple experimental blood cell samples includes: Calculate the mean of the dispersion of the multiple experimental blood cell samples to obtain the mean dispersion. Calculate the mean of the frequency standard deviations for the multiple experimental blood cell samples to obtain the mean frequency standard deviation; The allowable range of dispersion is determined based on the mean of the degree of dispersion and the mean of the standard deviation of the frequency. The formula for calculating the mean of the degree of dispersion is as follows: In the above formula, The mean of the dispersion; Indicates the dispersion of the k-th experimental blood cell sample. Indicator test blood cell count; The formula for calculating the mean of the standard deviation of the frequency is: In the above formula, Mean of standard deviation of the number of indications; Indicates the standard deviation of the number of blood cell samples in the k-th experiment; The discrete allowable range is expressed as: In the above formula, The default value is less than 1.
2. The method according to claim 1, characterized in that, The formula for calculating the average number of occurrences is: In the above formula, Instruction No. The number of particles of signal strength class, where N is the total number of signal strength classes. Indicates the average of the stated times; The formula for calculating the standard deviation of the frequency is: In the above formula, Indicates the standard deviation of the number; The formula for calculating the coefficient of variation is: In the above formula, Indicates the coefficient of variation.
3. The method according to claim 1, characterized in that, Following the particle distribution of the statistical signal intensity, the following is also included: The particle distribution is filtered; the filtering formula is as follows: In the above formula, This shows the particle distribution after filtering. This represents the particle distribution before filtering, where i indicates the intensity of the i-th type of signal, and N indicates the total number of signal types. Indicator mean, Indicative standard deviation.
4. A device for determining insufficient dosage of hemolytic agent, characterized in that, The method according to any one of claims 1-3 is applied to the determining device, the device comprising: A discrete allowable range determination module is used to acquire a set of pulse signals from a target blood cell sample at a preset scattering angle; wherein the target blood cell sample is any one of multiple experimental blood cell samples, all of which are blood cell samples obtained after sufficient hemolytic agent treatment; the module identifies the signal intensity of each pulse signal in the pulse signal set and statistically analyzes the particle distribution of the signal intensity; wherein the particle distribution indicates the number of blood cell particles with different signal intensities; the module calculates the discreteness of the target blood cell sample in terms of signal intensity based on the particle distribution to obtain the discreteness of the multiple experimental blood cell samples; and the discrete allowable range is determined by combining the discreteness of the multiple experimental blood cell samples. The judgment module is used to calculate the degree of dispersion of the blood cell sample to be tested in terms of signal intensity. If the degree of dispersion is not within the allowable range of dispersion, it is determined that the current dose of hemolytic agent is insufficient. The blood cell sample to be tested is a blood cell sample obtained after treatment with the current hemolytic agent.
5. A computer-readable storage medium, characterized in that, The system contains a computer program that, when executed by a processor, causes the processor to perform the steps of the method as described in any one of claims 1 to 3.
6. A device for determining insufficient dosage of hemolytic agent, characterized in that, It includes a memory and a processor, the memory storing a computer program that, when executed by the processor, causes the processor to perform the steps of the method as described in any one of claims 1 to 3.